IDH2 and central nervous system cancer: Although IDH mutations are retained upon glioma recurrence, mutant IDH1 may convert its biological role from driver to passenger [104] and in some patients neither IDH1 nor the oncometabolite 2HG are strictly required for clonal expansion at recurrence [105].